|
ATE556713T1
(de)
|
1999-01-13 |
2012-05-15 |
Bayer Healthcare Llc |
Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
HU230302B1
(hu)
|
2000-10-20 |
2015-12-28 |
Eisai R&D Management Co., Ltd. |
Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
|
|
AU2002351196A1
(en)
†
|
2001-12-03 |
2003-06-17 |
Bayer Pharmaceuticals Corporation |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
AU2003209116A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
|
US8299108B2
(en)
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
DK1499311T3
(da)
|
2002-03-29 |
2010-03-08 |
Novartis Vaccines & Diagnostic |
Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
|
|
AU2003246972A1
(en)
|
2002-08-06 |
2004-02-23 |
Astrazeneca Ab |
Condensed pyridines and pyrimidines with tie2 (tek) activity
|
|
MXPA05001536A
(es)
*
|
2002-08-30 |
2005-04-19 |
Eisai Co Ltd |
Derivados aromaticos que contienen nitrogeno.
|
|
US7365209B2
(en)
|
2003-02-11 |
2008-04-29 |
Pharmacopeia, Inc. |
Nitrogen heterocycle biaryls for osteoporosis and other diseases
|
|
US7531553B2
(en)
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
EP2258365B1
(en)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
|
JP2006521345A
(ja)
*
|
2003-03-28 |
2006-09-21 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
ニコチン性アセチルコリン受容体の正のアロステリック調節剤
|
|
PT1636585E
(pt)
|
2003-05-20 |
2008-03-27 |
Bayer Pharmaceuticals Corp |
Diarilureias com actividade inibidora de cinase
|
|
US6887798B2
(en)
|
2003-05-30 |
2005-05-03 |
International Business Machines Corporation |
STI stress modification by nitrogen plasma treatment for improving performance in small width devices
|
|
EP1653951B1
(en)
*
|
2003-07-11 |
2011-12-28 |
Merck Patent GmbH |
Benzimidazole derivatives as raf kinase inhibitors
|
|
NZ544920A
(en)
|
2003-07-23 |
2009-11-27 |
Bayer Healthcare Llc |
4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
|
|
DE10334663A1
(de)
*
|
2003-07-30 |
2005-03-10 |
Merck Patent Gmbh |
Harnstoffderivate
|
|
DE10337942A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Merck Patent Gmbh |
Aminobenzimidazolderivate
|
|
DE10342503A1
(de)
*
|
2003-09-12 |
2005-04-14 |
Merck Patent Gmbh |
Benzyl-Benzimidazolylderivate
|
|
DE10344223A1
(de)
*
|
2003-09-24 |
2005-04-21 |
Merck Patent Gmbh |
1,3-Benzoxazolylderivate als Kinase-Inhibitoren
|
|
EP1682126B1
(en)
|
2003-10-16 |
2009-07-01 |
Novartis Vaccines and Diagnostics, Inc. |
Substituted benzazoles and use thereof as inhibitors of raf kinase
|
|
DE10349587A1
(de)
*
|
2003-10-24 |
2005-05-25 |
Merck Patent Gmbh |
Benzimidazolylderivate
|
|
CN100450998C
(zh)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
|
US20050171172A1
(en)
*
|
2003-11-13 |
2005-08-04 |
Ambit Biosciences Corporation |
Amide derivatives as PDGFR modulators
|
|
DE10352979A1
(de)
*
|
2003-11-13 |
2005-06-09 |
Merck Patent Gmbh |
Pyridopyrimidinone
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
EP1718637A2
(en)
*
|
2004-02-26 |
2006-11-08 |
MERCK PATENT GmbH |
Benzimidazolyl derivatives as kinase inhibitors
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
|
CA2564325A1
(en)
|
2004-04-30 |
2005-11-24 |
Bayer Pharmaceuticals Corporation |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
|
US20090181092A1
(en)
*
|
2004-07-16 |
2009-07-16 |
Spinal Restoration, Inc. |
Methods for Treating Joints and Discs with a Carrier Matrix and Cells
|
|
EP1797881B1
(en)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medicinal composition with improved stability and reduced gelation properties
|
|
CN102391203A
(zh)
*
|
2004-09-28 |
2012-03-28 |
三共株式会社 |
制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
|
|
JP4789180B2
(ja)
*
|
2004-09-28 |
2011-10-12 |
第一三共株式会社 |
６−置換−１−メチル−１−ｈ−ベンズイミダゾール誘導体の製造方法及びその製造中間体
|
|
DE502005002697D1
(de)
*
|
2004-10-13 |
2008-03-13 |
Merck Patent Gmbh |
Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
|
|
BRPI0515991A
(pt)
|
2004-10-13 |
2008-08-19 |
Merck Patent Gmbh |
derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
|
|
GB0423554D0
(en)
*
|
2004-10-22 |
2004-11-24 |
Cancer Rec Tech Ltd |
Therapeutic compounds
|
|
DE102004054216A1
(de)
|
2004-11-10 |
2006-05-11 |
Merck Patent Gmbh |
Substituierte 4-Amino-pyridopyrimidinone
|
|
US7576090B2
(en)
|
2004-12-27 |
2009-08-18 |
4Sc Ag |
Benzazole analogues and uses thereof
|
|
EP1674466A1
(en)
*
|
2004-12-27 |
2006-06-28 |
4Sc Ag |
2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
|
|
EP2281901B1
(en)
|
2005-08-02 |
2013-11-27 |
Eisai R&D Management Co., Ltd. |
Anti-tumour pharmaceutical composition with angiogenesis inhibitors
|
|
US7202513B1
(en)
|
2005-09-29 |
2007-04-10 |
International Business Machines Corporation |
Stress engineering using dual pad nitride with selective SOI device architecture
|
|
JP5368099B2
(ja)
|
2005-10-07 |
2013-12-18 |
ゲルベ |
ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
|
|
US8986650B2
(en)
|
2005-10-07 |
2015-03-24 |
Guerbet |
Complex folate-NOTA-Ga68
|
|
RS56600B1
(sr)
|
2006-04-19 |
2018-02-28 |
Novartis Ag |
6-o-supstituisana jedinjenja benzoksazola i benzotiazola i postupci inhibicije csf-1r signalinga
|
|
US7951819B2
(en)
|
2006-04-26 |
2011-05-31 |
Cancer Research Technology Limited |
Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
|
|
BRPI0711358A2
(pt)
|
2006-05-09 |
2011-09-27 |
Pfizer Prod Inc |
derivados do ácido cicloalquilamino e suas composições farmacêuticas
|
|
EP2036557B1
(en)
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
|
JP2010504362A
(ja)
*
|
2006-09-25 |
2010-02-12 |
アレテ セラピューティクス， インコーポレイテッド |
可溶性エポキシドヒドロラーゼ阻害剤
|
|
JP2010505767A
(ja)
*
|
2006-09-28 |
2010-02-25 |
アレテ セラピューティクス， インコーポレイテッド |
可溶性エポキシドヒドロラーゼ阻害剤
|
|
AU2008211952B2
(en)
|
2007-01-29 |
2012-07-19 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
|
CL2008001626A1
(es)
|
2007-06-05 |
2009-06-05 |
Takeda Pharmaceuticals Co |
Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
|
|
US8431608B2
(en)
|
2007-08-17 |
2013-04-30 |
Icagen Inc. |
Heterocycles as potassium channel modulators
|
|
AU2008289101A1
(en)
*
|
2007-08-17 |
2009-02-26 |
Icagen, Inc. |
Heterocycles as potassium channel modulators
|
|
WO2009025358A1
(ja)
|
2007-08-23 |
2009-02-26 |
Takeda Pharmaceutical Company Limited |
複素環化合物およびその用途
|
|
EP2184285B1
(en)
*
|
2007-08-29 |
2015-11-04 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
JP5638244B2
(ja)
|
2007-11-09 |
2014-12-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
|
CN101945869B
(zh)
|
2007-12-19 |
2014-06-18 |
癌症研究技术有限公司 |
吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
|
|
JPWO2009128520A1
(ja)
|
2008-04-18 |
2011-08-04 |
塩野義製薬株式会社 |
Ｐｉ３ｋ阻害活性を有する複素環化合物
|
|
GB0807609D0
(en)
*
|
2008-04-25 |
2008-06-04 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
US8445509B2
(en)
|
2008-05-08 |
2013-05-21 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic derivatives and use thereof
|
|
CA2729012A1
(en)
|
2008-06-27 |
2009-12-30 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
US8697874B2
(en)
|
2008-12-01 |
2014-04-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
JO3101B1
(ar)
*
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
|
FR2942227B1
(fr)
|
2009-02-13 |
2011-04-15 |
Guerbet Sa |
Utilisation de tampons pour la complexation de radionucleides
|
|
WO2010126922A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Glaxosmithkline Llc |
Benzimidazolecarboxamides as inhibitors of fak
|
|
WO2011092469A1
(en)
|
2010-02-01 |
2011-08-04 |
Cancer Research Technology Limited |
1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
|
|
DK2536285T3
(en)
|
2010-02-18 |
2018-07-16 |
Vtv Therapeutics Llc |
Substituted fused imidazole derivatives, pharmaceutical compositions and methods for their use
|
|
US8759535B2
(en)
|
2010-02-18 |
2014-06-24 |
High Point Pharmaceuticals, Llc |
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
|
|
MX2012014776A
(es)
|
2010-06-25 |
2013-01-29 |
Eisai R&D Man Co Ltd |
Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
|
|
MX342481B
(es)
|
2010-09-03 |
2016-09-30 |
Genentech Inc * |
Nuevos compuestos y composiciones para la inhibicion de nampt.
|
|
FR2968999B1
(fr)
|
2010-12-20 |
2013-01-04 |
Guerbet Sa |
Nanoemulsion de chelate pour irm
|
|
MX2013009931A
(es)
|
2011-04-18 |
2013-10-01 |
Eisai R&D Man Co Ltd |
Agentes terapeuticos contra tumores.
|
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
FR2980364B1
(fr)
|
2011-09-26 |
2018-08-31 |
Guerbet |
Nanoemulsions et leur utilisation comme agents de contraste
|
|
US9334239B2
(en)
|
2012-12-21 |
2016-05-10 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
FR3001154B1
(fr)
|
2013-01-23 |
2015-06-26 |
Guerbet Sa |
Magneto-emulsion vectorisee
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
HK1223307A1
(zh)
*
|
2013-05-30 |
2017-07-28 |
Kala Pharmaceuticals, Inc. |
新型化合物和其用途
|
|
GB201320732D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Methods of chemical synthesis
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
CN106660964B
(zh)
|
2014-08-28 |
2021-09-03 |
卫材R&D管理有限公司 |
高纯度喹啉衍生物及其生产方法
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
WO2016089648A1
(en)
|
2014-12-01 |
2016-06-09 |
Vtv Therapeutics Llc |
Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
|
|
PL3263106T3
(pl)
|
2015-02-25 |
2024-04-02 |
Eisai R&D Management Co., Ltd. |
Sposób tłumienia goryczy pochodnej chinoliny
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
ES2886107T3
(es)
|
2015-06-16 |
2021-12-16 |
Prism Biolab Co Ltd |
Antineoplásico
|
|
AU2016309356B2
(en)
|
2015-08-20 |
2021-06-24 |
Eisai R&D Management Co., Ltd. |
Tumor therapeutic agent
|
|
EP3383852A4
(en)
*
|
2015-11-30 |
2019-08-28 |
Children's Medical Center Corporation |
COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
|
KR102341660B1
(ko)
|
2016-09-19 |
2021-12-23 |
노파르티스 아게 |
Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
|
|
MX380144B
(es)
|
2017-02-08 |
2025-03-12 |
Eisai R&D Man Co Ltd |
Composicion farmaceutica de tratamiento de tumores.
|
|
CN110494166B
(zh)
|
2017-05-02 |
2022-11-08 |
诺华股份有限公司 |
组合疗法
|
|
CA3061888A1
(en)
|
2017-05-16 |
2018-11-22 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
CN107954939B
(zh)
*
|
2017-12-07 |
2019-09-17 |
福建医科大学 |
一种微波辐射下n,n-二甲基氨基硫代甲酰氯衍生物催化合成苯并咪唑衍生物的方法
|
|
US12415816B2
(en)
|
2018-11-07 |
2025-09-16 |
Dana-Farber Cancer Institute, Inc. |
Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
|
|
US12358915B2
(en)
|
2019-04-05 |
2025-07-15 |
STORM Therapeutics Ltd. |
METTL3 inhibitory compounds
|
|
BR112021022335A2
(pt)
|
2019-05-13 |
2021-12-28 |
Novartis Ag |
Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
|
|
EP4146639A1
(en)
|
2020-05-06 |
2023-03-15 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
|
|
US20230391753A1
(en)
*
|
2020-10-19 |
2023-12-07 |
Korea University Research And Business Foundation |
Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof and use thereof
|
|
TW202241889A
(zh)
|
2020-12-23 |
2022-11-01 |
美商雅捷可斯治療公司 |
作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
|
|
WO2023086320A1
(en)
|
2021-11-09 |
2023-05-19 |
Ajax Therapeutics, Inc. |
Forms and compositions of inhibitors of jak2
|
|
JP7782035B2
(ja)
|
2021-11-09 |
2025-12-08 |
エイジャックス セラピューティクス， インコーポレイテッド |
Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
|
|
TW202346485A
(zh)
|
2022-03-28 |
2023-12-01 |
瑞士商杭斯曼高級材料公司 |
基於2-羥基萘-3-羧酸的分散偶氮染料
|
|
CN115724837B
(zh)
*
|
2022-10-26 |
2024-07-23 |
中国人民解放军海军军医大学 |
一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用
|